Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Towards The Development of a Biologically Functional Tissue Engineered Vascular Graft

Ardila, Diana Catalina (2019) Towards The Development of a Biologically Functional Tissue Engineered Vascular Graft. Doctoral Dissertation, University of Pittsburgh. (Unpublished)

[img] PDF
Restricted to University of Pittsburgh users only until 23 January 2024.

Download (3MB) | Request a Copy


Coronary artery disease (CAD) is the leading cause of death worldwide [1], and it is predicted that 23 million deaths will be attributed to CAD by 2030. Treatment of CAD has required over 400,000 coronary artery bypass graft (CABG) surgeries every year [2], representing a cost to the country of nearly $439 billion in direct and indirect expenses annually [3]. As autologous veins are often unavailable for in CABG surgeries [4, 5], and commercially available synthetic grafts have shown limited efficacy when used in small diameter vessels [5-7], a readily available tissue engineered vascular graft (TEVG) for use in CABG surgeries would provide drastic improvements in patient care. Despite significant recent progress [7, 8], the development of a biologically functional TEVG that is biocompatible, biofunctional, and anti-thrombogenic has remained elusive [9, 10]. The primary goal of this dissertation is to fabricate a TEVG that supports and modulates the growth and collagen production of vascular smooth muscle cells (VSMCs) and promotes the formation of a functional endothelium. For this purpose, an initial assessment of biocompatibility was performed by culturing SMCs in gelatin/fibrinogen electrospun scaffolds, using exogenous TGFβ2 to modulate cell response. It was demonstrated that that TGFβ2 had a differential effect on cell proliferation, migration, and collagen deposition of SMCs growing in our biopolymer materials. In order to provide additional biofunctionality to the TEVG, a tubular scaffold able to release TGFβ2 was fabricated. The combination of gelatin and PCL at different ratios allowed elution tunability. The released TGFβ2 was bioactive and was able to modulate SMCs growth in vitro and in 3D culture. To evaluate anti-thrombogenicity and perform an additional assessment of biocompatibility, human derived endothelial cells (hCB-ECs) were cultured in surface modified gelatin/fibrinogen/PCL electrospun scaffolds. hCB-ECs growing in the scaffolds showed similar or superior behavior to human umbilical vein ECs (HUVEC) in terms of platelet deposition and activation, producing eNOS, and responding to a proinflammatory stimulus. Our data suggests that a biofunctional biopolymer based TEVG can be fabricated that can control SMC response and promote the formation of a functional endothelium


Social Networking:
Share |


Item Type: University of Pittsburgh ETD
Status: Unpublished
CreatorsEmailPitt UsernameORCID
Ardila, Diana Catalinadca13@pitt.edudca13
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Committee ChairVande Geest, Jonathanjpv20@pitt.edujpv20
Committee MemberWagner, Williamwagnerwr@upmc.eduwagnerwr
Committee MemberBrown, Bryanbrownb@upmc.edubrownb
Committee MemberDoetschman,
Date: 23 January 2019
Date Type: Publication
Defense Date: 26 September 2018
Approval Date: 23 January 2019
Submission Date: 1 October 2018
Access Restriction: 5 year -- Restrict access to University of Pittsburgh for a period of 5 years.
Number of Pages: 164
Institution: University of Pittsburgh
Schools and Programs: Swanson School of Engineering > Bioengineering
Degree: PhD - Doctor of Philosophy
Thesis Type: Doctoral Dissertation
Refereed: Yes
Uncontrolled Keywords: tissue engineered vascular graft, electrospinning, TGFb2, smooth muscle cells, human cord blood derived endothelial cells
References: ..................................................................................................................... 135 ix LIST OF TABLES 1. Centers for Disease Control and Prevention, N.C.f.H.S., Multiple Cause of Death 1999 2015 on CDC WONDER Online Database, released December 2016. Data are from the Multiple Cause of Death Files, 1999-2015, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed at 2016. 2. Serruys, P.W., et al., Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. Journal of the American College of Cardiology, 2005. 46(4): p. 575-581. 3. Benjamin, E.J., et al., Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation, 2017. 135(10): p. e146-e603. 4. McClure, M.J., et al., A three-layered electrospun matrix to mimic native arterial architecture using polycaprolactone, elastin, and collagen: a preliminary study. Acta Biomaterialia, 2010. 6(7): p. 2422-2433. 5. McClure, M., et al., Bioengineered vascular grafts: improving vascular tissue engineering through scaffold design. Journal of Drug Delivery Science and Technology, 2011. 21(3): p. 211-227. 6. Sell, S.A., et al., Electrospinning of collagen/biopolymers for regenerative medicine and cardiovascular tissue engineering. Advanced drug delivery reviews, 2009. 61(12): p. 1007-1019. 7. Byrom, M.J., M.K. Ng, and P.G. Bannon, Biomechanics and biocompatibility of the perfect conduit—can we build one? Annals of cardiothoracic surgery, 2013. 2(4): p. 435. 8. Ong, C.S., et al., Tissue engineered vascular grafts: current state of the field. Expert review of medical devices, 2017. 14(5): p. 383-392. 9. L'Heureux, N., et al., Technology insight: the evolution of tissue-engineered vascular grafts—from research to clinical practice. Nature Clinical Practice Cardiovascular Medicine, 2007. 4(7): p. 389-395. 10. Tan, A., et al., Tissue engineering vascular grafts a fortiori: looking back and going forward. Expert opinion on biological therapy, 2015. 15(2): p. 231-244. 11. Roger, V.L., et al., Heart disease and stroke statistics—2012 update a report from the American heart association. Circulation, 2012. 125(1): p. e2-e220. 12. Mozaffarian, D., et al., Executive Summary: Heart Disease and Stroke Statistics—2016 Update A Report From the American Heart Association. Circulation, 2016. 133(4): p. 447-454. 13. Go, A.S., et al., Heart disease and stroke statistics-2014 update. Circulation, 2014. 129(3). 14. Fuchs, J.R., B.A. Nasseri, and J.P. Vacanti, Tissue engineering: a 21st century solution to surgical reconstruction. The Annals of thoracic surgery, 2001. 72(2): p. 577-591. 15. Langer, R. and J.P. Vacanti, Tissue engineering. Science, 1993. 260(5110): p. 920-6. 16. Vacanti, J.P. and R. Langer, Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation. The Lancet, 1999. 354: p. S32-S34. 17. Chen, Q.-Z., et al., Biomaterials in cardiac tissue engineering: ten years of research survey. Materials Science and Engineering: R: Reports, 2008. 59(1): p. 1-37. 18. O'Brien, F.J., Biomaterials & scaffolds for tissue engineering. Materials Today, 2011. 14(3): p. 88-95. 19. Gunatillake, P.A. and R. Adhikari, Biodegradable synthetic polymers for tissue engineering. Eur Cell Mater, 2003. 5(1): p. 1-16. 20. Dhandayuthapani, B., et al., Polymeric scaffolds in tissue engineering application: a review. International Journal of Polymer Science, 2011. 2011. 21. Nikolovski, J. and D.J. Mooney, Smooth muscle cell adhesion to tissue engineering scaffolds. Biomaterials, 2000. 21(20): p. 2025-2032. 22. Kohane, D.S. and R. Langer, Polymeric biomaterials in tissue engineering. Pediatric research, 2008. 63(5): p. 487-491. 23. Oh, S.H. and J.H. Lee, Hydrophilization of synthetic biodegradable polymer scaffolds for improved cell/tissue compatibility. Biomedical Materials, 2013. 8(1): p. 014101. 24. Sell, S.A., et al., The use of natural polymers in tissue engineering: a focus on electrospun extracellular matrix analogues. Polymers, 2010. 2(4): p. 522-553. 25. Mano, J., et al., Natural origin biodegradable systems in tissue engineering and regenerative medicine: present status and some moving trends. Journal of the Royal Society Interface, 2007. 4(17): p. 999-1030. 26. Marler, J.J., et al., Transplantation of cells in matrices for tissue regeneration. Advanced drug delivery reviews, 1998. 33(1): p. 165-182. 27. Catto, V., et al., Vascular tissue engineering: recent advances in small diameter blood vessel regeneration. ISRN Vascular Medicine, 2014. 2014. 28. Faletra, F.F., N.G. Pandian, and S.Y. Ho, Coronary Artery Anatomy. Anatomy of the Heart by Multislice Computed Tomography: p. 88-107. 29. AHA. Whatch, learn live, Interactive cardiovascular library. 2018; Available from: 30. James, T.N., Anatomy of the coronary arteries. 1961: PB Hoeber. 31. Childs, G. Microanatomy web atlas. 1998; Available from: 32. Waller, B.F., et al., Anatomy, histology, and pathology of coronary arteries: A review relevant to new interventional and imaging techniques—Part I. Clinical cardiology, 1992. 15(6): p. 451-457. 33. Michiels, C., Endothelial cell functions. Journal of cellular physiology, 2003. 196(3): p. 430-443. 34. Rensen, S., P. Doevendans, and G. Van Eys, Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Netherlands Heart Journal, 2007. 15(3): p. 100 108. 35. Hanson, M.A., et al., Coronary artery disease. Primary Care: Clinics in Office Practice, 2013. 40(1): p. 1-16. 36. Centers for disease, c., and prevention. Coronary Artery Disease: Causes, Diagonosis & Prevention. 2015; Available from: 37. Wilson, P.W., et al., Prediction of coronary heart disease using risk factor categories. Circulation, 1998. 97(18): p. 1837-1847. 38. McCullough, P.A., Coronary artery disease. Clinical Journal of the American Society of Nephrology, 2007. 2(3): p. 611-616. 39. Kappetein, A.P., et al., Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. European Journal of Cardio-Thoracic Surgery, 2013. 43(5): p. 1006-1013. 40. Lytle, B.W. and D.M. Cosgrove, Coronary artery bypass surgery. Current problems in surgery, 1992. 29(10): p. 743-807. 41. System, M.N.H., Understanding Off-Pump Coronary Artery Bypass (CABG) Surgery. 2016. 42. Norouzi, M., et al., Protein encapsulated in electrospun nanofibrous scaffolds for tissue engineering applications. Polymer International, 2013. 62(8): p. 1250-1256. 43. Stegemann, J.P., S.N. Kaszuba, and S.L. Rowe, Review: advances in vascular tissue engineering using protein-based biomaterials. Tissue engineering, 2007. 13(11): p. 2601 2613. 44. Pashneh-Tala, S., S. MacNeil, and F. Claeyssens, The tissue-engineered vascular graft— past, present, and future. Tissue Engineering Part B: Reviews, 2015. 22(1): p. 68-100. 45. Greiner, A. and J.H. Wendorff, Electrospinning: a fascinating method for the preparation of ultrathin fibers. Angewandte Chemie International Edition, 2007. 46(30): p. 5670 5703. 46. Huang, Z.-M., et al., A review on polymer nanofibers by electrospinning and their applications in nanocomposites. Composites science and technology, 2003. 63(15): p. 2223-2253. 47. Stitzel, J.D., et al. Electrospraying and electrospinning of polymers for biomedical applications. Poly (lactic-co-glycolic acid) and poly (ethylene-co-vinylacetate). in International SAMPE technical conference. 2000. 48. Martínez-Pérez, C.A., et al., Scaffolds for tissue engineering via thermally induced phase separation, in Advances in Regenerative Medicine. 2011, InTech. 49. Guan, J., J.J. Stankus, and W.R. Wagner, Biodegradable elastomeric scaffolds with basic fibroblast growth factor release. Journal of Controlled Release, 2007. 120(1-2): p. 70-78. 50. Carrabba, M. and P. Madeddu, Current Strategies for the Manufacture of Small Size Tissue Engineering Vascular Grafts. Frontiers in bioengineering and biotechnology, 2018. 6: p. 41. 51. Wang, L., et al., Fabrication of tissue-engineered vascular grafts with stem cells and stem cell-derived vascular cells. Expert opinion on biological therapy, 2016. 16(3): p. 317-330. 52. Worth, N.F., et al., Vascular smooth muscle cell phenotypic modulation in culture is associated with reorganisation of contractile and cytoskeletal proteins. Cell motility and the cytoskeleton, 2001. 49(3): p. 130-145. 53. Beamish, J.A., et al., Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering. Tissue Engineering Part B: Reviews, 2010. 16(5): p. 467-491. 54. Deanfield, J.E., J.P. Halcox, and T.J. Rabelink, Endothelial function and dysfunction testing and clinical relevance. Circulation, 2007. 115(10): p. 1285-1295. 55. Marti, C.N., et al., Endothelial dysfunction, arterial stiffness, and heart failure. Journal of the American College of Cardiology, 2012. 60(16): p. 1455-1469. 56. Wang, Z., et al., Novel biomaterial strategies for controlled growth factor delivery for biomedical applications. NPG Asia Materials, 2017. 9(10): p. e435. 57. King, T.W. and C.W. Patrick Jr, Development and in vitro characterization of vascular endothelial growth factor (VEGF)‐loaded poly (DL‐lactic‐co‐glycolic acid)/poly (ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique. Journal of Biomedical Materials Research: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials, 2000. 51(3): p. 383 390. 58. Masters, K.S., Covalent growth factor immobilization strategies for tissue repair and regeneration. Macromolecular bioscience, 2011. 11(9): p. 1149-1163. 59. Shireman, P.K. and H.P. Greisler, Mitogenicity and release of vascular endothelial growth factor with and without heparin from fibrin glue. Journal of vascular surgery, 2000. 31(5): p. 936-943. 60. Pugh, R.J., et al., Transmembrane protein 184A is a receptor required for vascular smooth muscle cell responses to heparin. Journal of Biological Chemistry, 2016. 291(10): p. 5326-5341. 61. Fritze, L.M., C.F. Reilly, and R.D. Rosenberg, An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. The Journal of cell biology, 1985. 100(4): p. 1041-1049. 62. Clowes, A.W. and M.M. Clowes, Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration. Circulation research, 1986. 58(6): p. 839-845. 63. Cindhuchao, N., et al., Heparin inhibits SMC growth in the presence of human and fetal bovine serum. Biochemical and biophysical research communications, 2003. 302(1): p. 84-88. 64. Antonova, L.V., et al., Vascular endothelial growth factor improves physico-mechanical properties and enhances endothelialization of poly (3-hydroxybutyrate-co-3 hydroxyvalerate)/poly (ε-caprolactone) small-diameter vascular grafts in vivo. Frontiers in pharmacology, 2016. 7: p. 230. 65. de Mel, A., et al., Biofunctionalization of biomaterials for accelerated in situ endothelialization: a review. Biomacromolecules, 2008. 9(11): p. 2969-2979. 66. Washington, K.S. and C.A. Bashur, Delivery of Antioxidant and Anti-inflammatory Agents for Tissue Engineered Vascular Grafts. Frontiers in pharmacology, 2017. 8: p. 659. 67. Strobel, H.A., et al., Cellular self-assembly with microsphere incorporation for growth factor delivery within engineered vascular tissue rings. Tissue Engineering Part A, 2017. 23(3-4): p. 143-155. 68. Gui, L., et al., Construction of tissue-engineered small-diameter vascular grafts in fibrin scaffolds in 30 days. Tissue Engineering Part A, 2014. 20(9-10): p. 1499-1507. 69. L'heureux, N., et al., Technology insight: the evolution of tissue-engineered vascular grafts—from research to clinical practice. Nature Reviews Cardiology, 2007. 4(7): p. 389. 70. Wang, G., et al., Origin and differentiation of vascular smooth muscle cells. The Journal of physiology, 2015. 593(14): p. 3013-3030. 71. Lannutti, J., et al., Electrospinning for tissue engineering scaffolds. Materials Science and Engineering: C, 2007. 27(3): p. 504-509. 72. Casscells, W., Smooth muscle cell growth factors. Progress in growth factor research, 1991. 3(3): p. 177-206. 73. Fuster, V., E.J. Topol, and E.G. Nabel, Atherothrombosis and coronary artery disease. 2005: Lippincott Williams & Wilkins. 74. Chen, P.-Y., et al., Fibroblast growth factor (FGF) signaling regulates transforming growth factor beta (TGFβ)-dependent smooth muscle cell phenotype modulation. Scientific reports, 2016. 6: p. 33407. 75. Yamashita, J.K., Expanding reprogramming to cardiovascular progenitors. Cell stem cell, 2016. 18(3): p. 299-301. 76. Liu, Y., et al., Transforming growth factor-beta1 upregulation triggers pulmonary artery smooth muscle cell proliferation and apoptosis imbalance in rats with hypoxic pulmonary hypertension via the PTEN/AKT pathways. The international journal of biochemistry & cell biology, 2016. 77: p. 141-154. 77. Goumans, M.-J. and P. ten Dijke, TGF-β signaling in control of cardiovascular function. Cold Spring Harbor perspectives in biology, 2018. 10(2): p. a022210. 78. Ardila, D.C., et al., TGFβ2 differentially modulates smooth muscle cell proliferation and migration in electrospun gelatin-fibrinogen constructs. Biomaterials, 2015. 37: p. 164 173. 79. Boileau, C., et al., TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nature genetics, 2012. 44(8): p. 916. 80. Ramnath, N., et al., Fibulin-4 deficiency increases TGF-β signalling in aortic smooth muscle cells due to elevated TGF-β2 levels. Scientific reports, 2015. 5: p. 16872. 81. Artman, M., et al., Cardiovascular Development and Congenital Malformations: Molecular & Genetic Mechanisms. 2008: John Wiley & Sons. 82. Azhar, M., et al., Transforming growth factor Beta2 is required for valve remodeling during heart development. Developmental Dynamics, 2011. 240(9): p. 2127-2141. 83. Doetschman, T., et al., Transforming growth factor beta signaling in adult cardiovascular diseases and repair. Cell and tissue research, 2012. 347(1): p. 203-223. 84. Molin, D.G., et al., Altered apoptosis pattern during pharyngeal arch artery remodelling is associated with aortic arch malformations in Tgfβ2 knock-out mice. Cardiovascular research, 2002. 56(2): p. 312-322. 85. Molin, D.G., et al., TGFb2 does not affect neural crest cell migration but is a key player in vascular remodeling during embryogenesis. Cardiovascular Development and Congenital Malformations, 2008: p. 148. 86. Balasubramanian, P., et al., Human cardiomyocyte interaction with electrospun fibrinogen/gelatin nanofibers for myocardial regeneration. Journal of Biomaterials Science, Polymer Edition, 2013. 24(14): p. 1660-1675. 87. Gallicchio, M.A., Culture of human smooth muscle cells, in Atherosclerosis. 2001, Springer. p. 137-146. 88. Gotlieb, A.I. and P. Boden, Porcine aortic organ culture: a model to study the cellular response to vascular injury. In vitro, 1984. 20(7): p. 535-542. 89. Williams, M.J., et al., Differences in the microstructure and biomechanical properties of the recurrent laryngeal nerve as a function of age and location. Journal of biomechanical engineering, 2014. 136(8): p. 081008. 90. Haskett, D., et al., Progressive alterations in microstructural organization and biomechanical response in the ApoE mouse model of aneurysm. Biomatter, 2013. 3(3). 91. Chen, X., et al., Second harmonic generation microscopy for quantitative analysis of collagen fibrillar structure. Nature protocols, 2012. 7(4): p. 654-669. 92. Lee, S.H., et al., Proliferation and differentiation of smooth muscle cell precursors occurs simultaneously during the development of the vessel wall. Developmental dynamics, 1997. 209(4): p. 342-352. 93. Long, X., et al., Smooth Muscle Calponin An Unconventional CArG-Dependent Gene That Antagonizes Neointimal Formation. Arteriosclerosis, thrombosis, and vascular biology, 2011. 31(10): p. 2172-2180. 94. Hughes, S. and T. Chan-Ling, Characterization of smooth muscle cell and pericyte differentiation in the rat retina in vivo. Investigative ophthalmology & visual science, 2004. 45(8): p. 2795-2806. 95. El-Mezgueldi, M., Calponin. The international journal of biochemistry & cell biology, 1996. 28(11): p. 1185-1189. 96. Skalli, O., et al., Alpha-smooth muscle actin, a differentiation marker of smooth muscle cells, is present in microfilamentous bundles of pericytes. Journal of Histochemistry & Cytochemistry, 1989. 37(3): p. 315-321. 97. Wu, S.-C., et al., Cell adhesion and proliferation enhancement by gelatin nanofiber scaffolds. Journal of Bioactive and Compatible Polymers, 2011. 26(6): p. 565-577. 98. Rungsiyanont, S., et al., Evaluation of biomimetic scaffold of gelatin-hydroxyapatite crosslink as a novel scaffold for tissue engineering: Biocompatibility evaluation with human PDL fibroblasts, human mesenchymal stromal cells, and primary bone cells. Journal of biomaterials applications, 2012. 27(1): p. 47-54. 99. Rosellini, E., et al., Preparation and characterization of alginate/gelatin blend films for cardiac tissue engineering. Journal of Biomedical Materials Research Part A, 2009. 91(2): p. 447-453. 100. Gardiner, E.E. and S.E. D'Souza, A mitogenic action for fibrinogen mediated through intercellular adhesion molecule-1. Journal of Biological Chemistry, 1997. 272(24): p. 15474-15480. 101. Moiseeva, E.P., Adhesion receptors of vascular smooth muscle cells and their functions. Cardiovascular research, 2001. 52(3): p. 372-386. 102. Sturge, J., et al., Fibrin monomer and fibrinopeptide B act additively to increase DNA synthesis in smooth muscle cells cultured from human saphenous vein. Journal of vascular surgery, 2001. 33(4): p. 847-853. 103. Ishida, T. and K. Tanaka, Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture. Atherosclerosis, 1982. 44(2): p. 161-174. 104. Rnjak-Kovacina, J., et al., Tailoring the porosity and pore size of electrospun synthetic human elastin scaffolds for dermal tissue engineering. Biomaterials, 2011. 32(28): p. 6729-6736. 105. Lee, J.B., et al., Highly porous electrospun nanofibers enhanced by ultrasonication for improved cellular infiltration. Tissue Engineering Part A, 2011. 17(21-22): p. 2695-2702. 106. Horst, M., et al., Increased porosity of electrospun hybrid scaffolds improved bladder tissue regeneration. Journal of Biomedical Materials Research Part A, 2014. 102(7): p. 2116-2124. 107. Owens, G.K., Regulation of differentiation of vascular smooth muscle cells. Physiological reviews, 1995. 75(3): p. 487-517. 108. Owens, G.K., M.S. Kumar, and B.R. Wamhoff, Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiological reviews, 2004. 84(3): p. 767-801. 109. Spin, J.M., L. Maegdefessel, and P.S. Tsao, Vascular smooth muscle cell phenotypic plasticity: focus on chromatin remodelling. Cardiovascular research, 2012. 95(2): p. 147 155. 110. Moses, M.A., M. Klagsbrun, and Y. Shing, The role of growth factors in vascular cell development and differentiation. International review of cytology, 1995. 161: p. 1-48. 111. Stegemann, J.P. and R.M. Nerem, Phenotype modulation in vascular tissue engineering using biochemical and mechanical stimulation. Annals of biomedical engineering, 2003. 31(4): p. 391-402. 112. Guo, X. and S.-Y. Chen, Transforming growth factor-β and smooth muscle differentiation. World journal of biological chemistry, 2012. 3(3): p. 41. 113. Kubota, K., et al., TGF-β stimulates collagen (I) in vascular smooth muscle cells via a short element in the proximal collagen promoter. Journal of Surgical Research, 2003. 109(1): p. 43-50. 114. Mann, B.K., R.H. Schmedlen, and J.L. West, Tethered-TGF-β increases extracellular matrix production of vascular smooth muscle cells. Biomaterials, 2001. 22(5): p. 439 444. 115. Blanchette, F., et al., TGFbeta1 regulates gene expression of its own converting enzyme furin. Journal of Clinical Investigation, 1997. 99(8): p. 1974. 116. Brisset, A.C., et al., Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro. Circulation research, 2007. 100(7): p. 1055-1062. 117. Burnstock, G., Purinergic signaling and vascular cell proliferation and death. Arteriosclerosis, thrombosis, and vascular biology, 2002. 22(3): p. 364-373. 118. Corrêa-Giannella, M.L., et al., Fibronectin glycation increases IGF-I induced proliferation of human aortic smooth muscle cells. Diabetology & metabolic syndrome, 2012. 4. 119. Gollasch, M., et al., K+ currents in human coronary artery vascular smooth muscle cells. Circulation research, 1996. 78(4): p. 676-688. 120. Hao, H., G. Gabbiani, and M.-L. Bochaton-Piallat, Arterial smooth muscle cell heterogeneity implications for atherosclerosis and restenosis development. Arteriosclerosis, thrombosis, and vascular biology, 2003. 23(9): p. 1510-1520. 121. Patel, S., et al., Characteristics of coronary smooth muscle cells and adventitial fibroblasts. Circulation, 2000. 101(5): p. 524-532. 122. Swindle, M., et al., Swine as models in biomedical research and toxicology testing. Veterinary Pathology Online, 2012. 49(2): p. 344-356. 123. Douglas, W.R., Of pigs and men and research. Space life sciences, 1972. 3(3): p. 226 234. 124. Keyes, J.T., et al., Design and demonstration of a microbiaxial optomechanical device for multiscale characterization of soft biological tissues with two-photon microscopy. Microscopy and Microanalysis, 2011. 17(02): p. 167-175. 125. Keyes, J.T., et al., Adaptation of a planar microbiaxial optomechanical device for the tubular biaxial microstructural and macroscopic characterization of small vascular tissues. Journal of biomechanical engineering, 2011. 133(7): p. 075001. 126. Benrashid, E., et al., Tissue engineered vascular grafts: Origins, development, and current strategies for clinical application. Methods, 2016. 99: p. 13-19. 127. Tan, A., et al., Tissue engineering vascular grafts a fortiori: looking back and going forward. Expert opinion on biological therapy, 2015. 15(2): p. 231-244. 128. Rychter, M., A. Baranowska-Korczyc, and J. Lulek, Progress and perspectives in bioactive agent delivery via electrospun vascular grafts. RSC Advances, 2017. 7(51): p. 32164-32184. 129. Han, J. and P.I. Lelkes, Drug-Eluting Vascular Grafts, in Focal Controlled Drug Delivery. 2014, Springer. p. 405-427. 130. DeLong, S.A., J.J. Moon, and J.L. West, Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. Biomaterials, 2005. 26(16): p. 3227-3234. 131. Tallawi, M., et al., Strategies for the chemical and biological functionalization of scaffolds for cardiac tissue engineering: a review. Journal of the Royal Society Interface, 2015. 12(108): p. 20150254. 132. Reed, S. and B. Wu, Sustained growth factor delivery in tissue engineering applications. Annals of biomedical engineering, 2014. 42(7): p. 1528-1536. 133. Ham, T.R., M. Farrag, and N.D. Leipzig, Covalent growth factor tethering to direct neural stem cell differentiation and self-organization. Acta biomaterialia, 2017. 53: p. 140-151. 134. Szulcek, R., et al., The covalently immobilized antimicrobial peptide LL37 acts as a VEGF mimic and stimulates endothelial cell proliferation. Biochemical and biophysical research communications, 2018. 496(3): p. 887-890. 135. Leong, N.L., et al., In vitro and in vivo evaluation of heparin mediated growth factor release from tissue‐engineered constructs for anterior cruciate ligament reconstruction. Journal of Orthopaedic Research, 2015. 33(2): p. 229-236. 136. Liu, Y., et al., Sustained dual release of placental growth factor-2 and bone morphogenic protein-2 from heparin-based nanocomplexes for direct osteogenesis. International journal of nanomedicine, 2016. 11: p. 1147. 137. Liang, Y. and K.L. Kiick, Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications. Acta biomaterialia, 2014. 10(4): p. 1588 1600. 138. Munj, H.R., J.J. Lannutti, and D.L. Tomasko, Understanding drug release from PCL/gelatin electrospun blends. Journal of Biomaterials Applications, 2017. 31(6): p. 933-949. 139. Wolf, M.T., et al., Naturally derived and synthetic scaffolds for skeletal muscle reconstruction. Advanced drug delivery reviews, 2015. 84: p. 208-221. 140. Goyal, R., et al., Development of hybrid scaffolds with natural extracellular matrix deposited within synthetic polymeric fibers. Journal of Biomedical Materials Research Part A, 2017. 105(8): p. 2162-2170. 141. Norouzi, M., et al., PLGA/gelatin hybrid nanofibrous scaffolds encapsulating EGF for skin regeneration. Journal of Biomedical Materials Research Part A, 2015. 103(7): p. 2225-2235. 142. Stankus, J.J., et al., Hybrid nanofibrous scaffolds from electrospinning of a synthetic biodegradable elastomer and urinary bladder matrix. Journal of Biomaterials Science, Polymer Edition, 2008. 19(5): p. 635-652. 143. Fukunishi, T., et al., Tissue-engineered small diameter arterial vascular grafts from cell free nanofiber PCL/chitosan scaffolds in a sheep model. PLoS One, 2016. 11(7): p. e0158555. 144. Heydarkhan-Hagvall, S., et al., Three-dimensional electrospun ECM-based hybrid scaffolds for cardiovascular tissue engineering. Biomaterials, 2008. 29(19): p. 2907 2914. 145. Fu, W., et al., Electrospun gelatin/PCL and collagen/PLCL scaffolds for vascular tissue engineering. International journal of nanomedicine, 2014. 9: p. 2335. 146. Gautam, S., A.K. Dinda, and N.C. Mishra, Fabrication and characterization of PCL/gelatin composite nanofibrous scaffold for tissue engineering applications by electrospinning method. Materials Science and Engineering: C, 2013. 33(3): p. 1228 1235. 147. Nada, A.A., et al., Eco-friendly gelatin-based electrospun fibers to control the release of chloramphenicol. Fibers and Polymers, 2016. 17(12): p. 1985-1994. 148. Sohier, J., et al., Tailored release of TGF-β1 from porous scaffolds for cartilage tissue engineering. International journal of pharmaceutics, 2007. 332(1-2): p. 80-89. 149. Wang, Z., et al., Evaluation of emulsion electrospun polycaprolactone/hyaluronan/epidermal growth factor nanofibrous scaffolds for wound healing. Journal of biomaterials applications, 2016. 30(6): p. 686-698. 150. Wang, K., et al., Enhanced vascularization in hybrid PCL/gelatin fibrous scaffolds with sustained release of VEGF. BioMed research international, 2015. 2015. 151. Rose, J.B., et al., Gelatin-based materials in ocular tissue engineering. Materials, 2014. 7(4): p. 3106-3135. 152. Butler, M.F., Y.F. Ng, and P.D. Pudney, Mechanism and kinetics of the crosslinking reaction between biopolymers containing primary amine groups and genipin. Journal of Polymer Science Part A: Polymer Chemistry, 2003. 41(24): p. 3941-3953. 153. Lin, H.Y., et al., The Soluble Exoplasmic Domain of the Type II Transforming Growth Factor (TGF)-β Receptor A HETEROGENEOUSLY GLYCOSYLATED PROTEIN WITH HIGH AFFINITY AND SELECTIVITY FOR TGF-β LIGANDS. Journal of Biological Chemistry, 1995. 270(6): p. 2747-2754. 154. Tamimi, E., et al., Biomechanical comparison of glutaraldehyde-crosslinked gelatin fibrinogen electrospun scaffolds to porcine coronary arteries. Journal of biomechanical engineering, 2016. 138(1): p. 011001. 155. Ravi, S. and E.L. Chaikof, Biomaterials for vascular tissue engineering. Regenerative medicine, 2010. 5(1): p. 107-120. 156. Melchiorri, A., et al., Contrasting biofunctionalization strategies for the enhanced endothelialization of biodegradable vascular grafts. Biomacromolecules, 2015. 16(2): p. 437-446. 157. Nagiah, N., et al., Highly compliant vascular grafts with gelatin-sheathed coaxially structured nanofibers. Langmuir, 2015. 31(47): p. 12993-13002. 158. Pan, Y., et al., Small-diameter hybrid vascular grafts composed of polycaprolactone and polydioxanone fibers. Scientific Reports, 2017. 7(1): p. 3615. 159. Tamimi, E., et al., Biomechanical Comparison of Glutaraldehyde-Crosslinked Gelatin Fibrinogen Electrospun Scaffolds to Porcine Coronary Arteries. Journal of biomechanical engineering, 2016. 138(1): p. 011001. 160. Weber, B., S.M. Zeisberger, and S.P. Hoerstrup, Umbilical Cord Blood-Derived Endothelial Progenitor Cells for Cardiovascular Tissue Engineering, in Perinatal Stem Cells. 2014, Springer. p. 325-336. 161. Stroncek, J.D., et al., Comparison of endothelial cell phenotypic markers of late outgrowth endothelial progenitor cells isolated from patients with coronary artery disease and healthy volunteers. Tissue Engineering Part A, 2009. 15(11): p. 3473-3486. 162. Cai, H., et al., MnSOD marks cord blood late outgrowth endothelial cells and accompanies robust resistance to oxidative stress. Biochemical and biophysical research communications, 2006. 350(2): p. 364-369. 163. Bompais, H., et al., Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. Blood, 2004. 103(7): p. 2577-2584. 164. Schmidt, D., et al., Umbilical cord blood derived endothelial progenitor cells for tissue engineering of vascular grafts. The Annals of thoracic surgery, 2004. 78(6): p. 2094 2098. 165. Brown, M.A., et al., Characterization of umbilical cord blood-derived late outgrowth endothelial progenitor cells exposed to laminar shear stress. Tissue Engineering Part A, 2009. 15(11): p. 3575-3587. 166. Brown, M.A., et al., Human Umbilical Cord Blood-Derived Endothelial Cells Reendothelialize Vein Grafts and Prevent Thrombosis. Arteriosclerosis, thrombosis, and vascular biology, 2010. 30(11): p. 2150-2155. 167. Jung, Y., et al., Scaffold-free, human mesenchymal stem cell-based tissue engineered blood vessels. Scientific reports, 2015. 5: p. 15116. 168. Javed, M.J., et al., Endothelial colony forming cells and mesenchymal stem cells are enriched at different gestational ages in human umbilical cord blood. Pediatric Research, 2008. 64(1): p. 68-73. 169. Brown, M.E., et al., Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PloS one, 2010. 5(6): p. e11373. 170. Ashton, J.H., et al., Polymeric endoaortic paving: Mechanical, thermoforming, and degradation properties of polycaprolactone/polyurethane blends for cardiovascular applications. Acta biomaterialia, 2011. 7(1): p. 287-294. 171. Sasidharan, A., et al., Simple device to determine the pressure applied by pressure clips for the treatment of earlobe keloids. Indian Journal of Plastic Surgery, 2015. 48(3): p. 293. 172. Jesty, J. and D. Bluestein, Acetylated prothrombin as a substrate in the measurement of the procoagulant activity of platelets: elimination of the feedback activation of platelets by thrombin. Analytical biochemistry, 1999. 272(1): p. 64-70. 173. Merkle, V.M., et al., Hemocompatibility of Poly (vinyl alcohol)-Gelatin Core-Shell Electrospun Nanofibers: A Scaffold for Modulating Platelet Deposition and Activation. ACS applied materials & interfaces, 2015. 7(15): p. 8302-8312. 174. Merkle, V.M., et al., Core-shell PVA/gelatin electrospun nanofibers promote human umbilical vein endothelial cell and smooth muscle cell proliferation and migration. Acta biomaterialia, 2015. 27: p. 77-87. 175. Kuwahara, M., et al., Platelet shape changes and adhesion under high shear flow. Arteriosclerosis, thrombosis, and vascular biology, 2002. 22(2): p. 329-334. 176. O'Carroll, S.J., et al., Pro-inflammatory TNFα and IL-1β differentially regulate the inflammatory phenotype of brain microvascular endothelial cells. Journal of neuroinflammation, 2015. 12(1): p. 131. 177. Burrows, M.C., et al., Hybrid scaffolds built from PET and collagen as a model for vascular graft architecture. Macromolecular bioscience, 2012. 12(12): p. 1660-1670. 178. Ma, Z., et al., Surface engineering of electrospun polyethylene terephthalate (PET) nanofibers towards development of a new material for blood vessel engineering. Biomaterials, 2005. 26(15): p. 2527-2536. 179. Cassady, A.I., N.M. Hidzir, and L. Grøndahl, Enhancing expanded poly (tetrafluoroethylene)(ePTFE) for biomaterials applications. Journal of Applied Polymer Science, 2014. 131(15). 180. Takagi, H., et al., A contemporary meta-analysis of Dacron versus polytetrafluoroethylene grafts for femoropopliteal bypass grafting. Journal of vascular surgery, 2010. 52(1): p. 232-236. 181. Jeschke, M.G., et al., Polyurethane vascular prostheses decreases neointimal formation compared with expanded polytetrafluoroethylene. Journal of vascular surgery, 1999. 29(1): p. 168-176. 182. MüLLER-HüLSBECK, S., et al., Experience on endothelial cell adhesion on vascular stents and stent-grafts: first in vitro results. Investigative radiology, 2002. 37(6): p. 314 320. 183. Ren, X., et al., Surface modification and endothelialization of biomaterials as potential scaffolds for vascular tissue engineering applications. Chemical Society Reviews, 2015. 44(15): p. 5680-5742. 184. Li, Q., et al., Functionalization of the surface of electrospun poly (epsilon-caprolactone) mats using zwitterionic poly (carboxybetaine methacrylate) and cell-specific peptide for endothelial progenitor cells capture. Materials Science and Engineering: C, 2013. 33(3): p. 1646-1653. 185. Xiong, G.M., et al., Endothelial cell thrombogenicity is reduced by ATRP-mediated grafting of gelatin onto PCL surfaces. Journal of Materials Chemistry B, 2014. 2(5): p. 485-493. 186. Choi, W.S., et al., Enhanced Patency and Endothelialization of Small-Caliber Vascular Grafts Fabricated by Coimmobilization of Heparin and Cell-Adhesive Peptides. ACS applied materials & interfaces, 2016. 8(7): p. 4336-4346. 187. Huang, Y., et al., In vitro characterization of chitosan-gelatin scaffolds for tissue engineering. Biomaterials, 2005. 26(36): p. 7616-7627. 188. Wu, S.-C., et al., Cell adhesion and proliferation enhancement by gelatin nanofiber scaffolds. Journal of Bioactive and Compatible Polymers, 2011: p. 0883911511423563. 189. D'Souza, S.E., M.H. Ginsberg, and E.F. Plow, Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends in biochemical sciences, 1991. 16: p. 246-250. 190. Ruoslahti, E. and M.D. Pierschbacher, Arg-Gly-Asp: a versatile cell recognition signal. Cell, 1986. 44(4): p. 517-518. 191. Widhe, M. and N.D. Shalaly, A fibronectin mimetic motif improves integrin mediated cell biding to recombinant spider silk matrices. Biomaterials, 2016. 74: p. 256-266. 192. Pierce, B.F., et al., Viability of Human Mesenchymal Stem Cells Seeded on Crosslinked Entropy‐Elastic Gelatin‐Based Hydrogels. Macromolecular bioscience, 2012. 12(3): p. 312-321. 193. Underwood, P.A., et al., Evidence for the location of a binding sequence for the α2β1 integrin of endothelial cells, in the β1 subunit of laminin. Biochemical Journal, 1995. 309(3): p. 765-771. 194. Saotome, T., et al., Introduction of VEGF or RGD sequences improves revascularization properties of Bombyx mori silk fibroin produced by transgenic silkworm. Journal of Materials Chemistry B, 2015. 3(35): p. 7109-7116. 195. Ingber, D.E., Fibronectin controls capillary endothelial cell growth by modulating cell shape. Proceedings of the National Academy of Sciences, 1990. 87(9): p. 3579-3583. 196. Bahou, W.F., C.L. Potter, and H. Mirza, The VLA-2 (alpha 2 beta 1) I domain functions as a ligand-specific recognition sequence for endothelial cell attachment and spreading: molecular and functional characterization. Blood, 1994. 84(11): p. 3734-3741. 197. Chen, M., et al., Role of fiber diameter in adhesion and proliferation of NIH 3T3 fibroblast on electrospun polycaprolactone scaffolds. Tissue Engineering, 2007. 13(3): p. 579-587. 198. Whited, B.M. and M.N. Rylander, The influence of electrospun scaffold topography on endothelial cell morphology, alignment, and adhesion in response to fluid flow. Biotechnology and bioengineering, 2014. 111(1): p. 184-195. 199. Adams, W.J., et al., Functional vascular endothelium derived from human induced pluripotent stem cells. Stem Cell Reports, 2013. 1(2): p. 105-113. 200. Van Rijssel, J., et al., The Rho-GEF Trio regulates a novel pro-inflammatory pathway through the transcription factor Ets2. Biology open, 2013. 2(6): p. 569-579. 201. Takahashi, M., et al., Monocyte-endothelial cell interaction induces expression of adhesion molecules on human umbilical cord endothelial cells. Cardiovascular research, 1996. 32(2): p. 422-429. 202. Blake, G.J. and P.M. Ridker, Novel clinical markers of vascular wall inflammation. Circulation research, 2001. 89(9): p. 763-771. 203. Qin, L., et al., SOCS1 prevents graft arteriosclerosis by preserving endothelial cell function. Journal of the American College of Cardiology, 2014. 63(1): p. 21-29. 204. Zou, Y., et al., Reduced neointima hyperplasia of vein bypass grafts in intercellular adhesion molecule-1-deficient mice. Circulation research, 2000. 86(4): p. 434-440. 205. Matsushita, H., et al., eNOS Activity Is Reduced in Senescent Human Endothelial Cells Preservation by hTERT Immortalization. Circulation research, 2001. 89(9): p. 793-798. 206. Tran, J., et al., Activation of Endothelial Nitric Oxide (eNOS) Occurs through Different Membrane Domains in Endothelial Cells. PloS one, 2016. 11(3): p. e0151556. 207. Ruan, T., et al., Shear-Induced Extracellular Regulated Kinase Signaling to eNOS is Increased When Autophagy is Compromised in Endothelial Cells. The FASEB Journal, 2015. 29(1 Supplement): p. 956.4. 208. Li, Y., et al., Effects of pulsatile shear stress on signaling mechanisms controlling nitric oxide production, endothelial nitric oxide synthase phosphorylation, and expression in ovine fetoplacental artery endothelial cells. Endothelium, 2005. 12(1-2): p. 21-39. 209. Yang, B. and V. Rizzo, Shear stress activates eNOS at the endothelial apical surface through β1 containing integrins and caveolae. Cellular and molecular bioengineering, 2013. 6(3): p. 346-354. 210. Do Kang, S., et al., Isolation of functional human endothelial cells from small volumes of umbilical cord blood. Annals of biomedical engineering, 2013. 41(10): p. 2181-2192. 211. Broos, K., et al., Platelets at work in primary hemostasis. Blood reviews, 2011. 25(4): p. 155-167. 212. Szabo, C., Alterations in nitric oxide production in various forms of circulatory shock. New horizons (Baltimore, Md.), 1995. 3(1): p. 2-32. 213. van Hinsbergh, V.W. Endothelium—role in regulation of coagulation and inflammation. in Seminars in immunopathology. 2012. Springer. 214. Cronenwett, J.L. and K.W. Johnston, Rutherford's vascular surgery. 2014: Elsevier Health Sciences. 215. Abou-Saleh, H., et al., Endothelial progenitor cells bind and inhibit platelet function and thrombus formation. Circulation, 2009. 120(22): p. 2230-2239. 216. Shirota, T., et al., Human endothelial progenitor cell-seeded hybrid graft: proliferative and antithrombogenic potentials in vitro and fabrication processing. Tissue engineering, 2003. 9(1): p. 127-136. 217. He, W., et al., Fabrication and endothelialization of collagen-blended biodegradable polymer nanofibers: potential vascular graft for blood vessel tissue engineering. Tissue engineering, 2005. 11(9-10): p. 1574-1588. 218. Lee, B., et al., Characterization and preparation of bio-tubular scaffolds for fabricating artificial vascular grafts by combining electrospinning and a co-culture system. Macromolecular Research, 2016. 24(2): p. 131-142. 219. Zhou, W., et al., Electrospun scaffolds of silk fibroin and poly (lactide-co-glycolide) for endothelial cell growth. Journal of Materials Science: Materials in Medicine, 2015. 26(1): p. 1-14. 220. Li, Y.-S.J., J.H. Haga, and S. Chien, Molecular basis of the effects of shear stress on vascular endothelial cells. Journal of biomechanics, 2005. 38(10): p. 1949-1971. 221. Sessa, W.C., eNOS at a glance. Journal of cell science, 2004. 117(12): p. 2427-2429. 222. Kolluru, G.K., et al., Shear stress promotes nitric oxide production in endothelial cells by sub-cellular delocalization of eNOS: A basis for shear stress mediated angiogenesis. Nitric Oxide, 2010. 22(4): p. 304-315. 223. Dimmeler, S., et al., Activation of nitric oxide synthase in endothelial cells by Akt dependent phosphorylation. Nature, 1999. 399(6736): p. 601-605. 224. Uematsu, M., et al., Regulation of endothelial cell nitric oxide synthase mRNA expression by shear stress. American Journal of Physiology-Cell Physiology, 1995. 269(6): p. C1371-C1378. 225. Buga, G.M., et al., Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension, 1991. 17(2): p. 187-193. 226. Hsieh, H.-J., et al., Shear-induced endothelial mechanotransduction: the interplay between reactive oxygen species (ROS) and nitric oxide (NO) and the pathophysiological implications. Journal of biomedical science, 2014. 21(1): p. 1-15. 227. Langer, R. and J. Vacanti, Tissue Engineering. Science, 1993. 260: p. 920-92. 228. Weinberg, C.B. and E. Bell, A blood vessel model constructed from collagen and cultured vascular cells. Science, 1986. 231(4736): p. 397-400. 229. L'Heureux, N., et al., In vitro construction of a human blood vessel from cultured vascular cells: a morphologic study. Journal of vascular surgery, 1993. 17(3): p. 499-509. 230. Muylaert, D.E., et al., Environmental influences on endothelial to mesenchymal transition in developing implanted cardiovascular tissue-engineered grafts. Tissue Engineering Part B: Reviews, 2015. 22(1): p. 58-67. 231. Goumans, M.-J., F. Lebrin, and G. Valdimarsdottir, Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends in cardiovascular medicine, 2003. 13(7): p. 301-307. 232. Pinto, M.T., et al., Endothelial mesenchymal transition: comparative analysis of different induction methods. Biological procedures online, 2016. 18(1): p. 10. 233. Stavropoulos-Giokas, C., D. Charron, and C. Navarrete, Cord Blood Stem Cells Medicine. 2014: Elsevier. 234. Zhang, L., R. Yang, and Z.C. Han, Transplantation of umbilical cord blood‐derived endothelial progenitor cells: a promising method of therapeutic revascularisation. European journal of haematology, 2006. 76(1): p. 1-8. 235. Chow, T., S. Mueller, and I.M. Rogers, Advances in Umbilical Cord Blood Therapy: Hematopoietic Stem Cell Transplantation and Beyond, in Advances in Stem Cell Therapy. 2017, Springer. p. 139-168.
Date Deposited: 23 Jan 2019 16:52
Last Modified: 23 Jan 2019 16:52


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item